{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-034907","form_type":"8-K","ticker":"BBLG","cik":"0001419554","company_name":"Bone Biologics Corp","filed_at":"2023-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.871103+00:00","generated_at":"2026-06-10T06:51:20.890258+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Bone Biologics receives Nasdaq delisting notice for bid price non-compliance","bullets":["Received Nasdaq staff determination to delist due to failure to maintain $1.00 minimum bid price.","Company plans to request a hearing before Nasdaq Hearings Panel to appeal the delisting determination.","Company is evaluating alternatives to regain compliance; no assurance of success.","If delisted, securities expected to trade on OTC Markets platform.","Company previously under mandatory Panel Monitor, making it ineligible for standard compliance period."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-034907","json":"https://secwatch.observer/filing/0001493152-23-034907.json","markdown":"https://secwatch.observer/filing/0001493152-23-034907.md","text":"https://secwatch.observer/filing/0001493152-23-034907.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419554/000149315223034907/0001493152-23-034907-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419554/000149315223034907/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T06:51:20.890258+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"62f6ef36006a735baefee3cd05f2cf2760725f69","claim":"Bone Biologics Corp received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"September 27, 2023, Bone Biologics Corporation (the “Company”) received a written notice (the “Notice”) from the staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it failed to comply with the $1.00 per share minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). As a result of the imposition of a mandatory Panel Monitor, as previously disclosed on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on May 19, 2023, the Company is not eligible for a compliance period to regain compliance with the minimum bid price requirement. Acco","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419554/000149315223034907/0001493152-23-034907-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}